Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.

摘要: BACKGROUND: Adjuvant chemotherapy for breast cancer is frequently accompanied by neutropenia requiring dose reduction or treatment delay that can potentially compromise therapeutic effectiveness. Recombinant granulocyte-colony stimulating factor (G-CSF) reduces the duration and severity of neutropenia. METHODS: Nineteen patients with newly diagnosed receiving adjuvant systemic met criteria due to All were treated G-CSF. The mean G-CSF therapy was five days. RESULTS: An increase in absolute neutrophil count seen cycles Chemotherapy delayed less often following use CONCLUSIONS: Breast who face delays reductions continue on full-dose intensity using supportive Prospective trials are needed accurately measure impact long-term disease control.